Tyme Technologies Stock Price

0.0643 (6.87%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Tyme Technologies Inc New TYME NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0643 6.87% 0.9998 19:42:42
Open Price Low Price High Price Close Price Previous Close
0.945 0.9326 0.99 0.9851 0.9355
Bid Price Ask Price Spread News
0.9511 0.9998 0.0487 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,212 418,338 $ 0.9607978 $ 401,938 265,592 0.85 - 2.85
Last Trade Time Type Quantity Stock Price Currency
19:52:41 formt 2,500 $ 0.9998 USD

Tyme Technologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 128.23M 130.17M 78.94M $ - $ - -0.18 -4.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Tyme Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TYME Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.961.00010.910.9489075297,2040.03984.15%
1 Month0.921.00010.850.9284066255,0050.07988.67%
3 Months1.01331.120.850.9832207373,580-0.0135-1.33%
6 Months1.611.830.851.17796,190-0.6102-37.9%
1 Year1.162.850.851.25647,217-0.1602-13.81%
3 Years4.068.300.851.96531,310-3.06-75.37%
5 Years4.49479.500.852.01487,973-3.49-77.76%

Tyme Technologies Description

Tyme Technologies Inc is the U.S based clinical-stage biotechnology company. The company is focused on the development and commercialization of targeted cancer therapeutics with a broad range of oncology indications for humans. SM 88, its proprietary drug candidate compound, is a novel compound that has the potential to alter defenses to oxidative stress and increase free radical availability to the cancer cell. The company is currently conducting a Phase II trial in prostate cancer.

Your Recent History
Tyme Techn..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.